ABL1 and acute leukemia: We hypothesized that a blood-based multiplex ddPCR assay of WT1, BIRC5 (survivin), and PRAME as a ratio against homeostatic ABL1 would detect MRD in the majority of relapsed refractory acute leukemias after HCT, at levels exceeding those of healthy individuals.